Get the latest news alerts: at Twitter.

Local Tech Wire

DURHAM, N.C. – (Nasdaq: TRMS), which developed and sells the HIV drug Fuzeon worldwide in partnership with Roche, made a $988,000 profit in the first quarter.

The company earned 4 cents per share even though royalties from Fuzeon declined to $1.9 million from $2 million a year ago.

Net Fuzeon sales declined 3 percent from one year ago to $17.3 million. Fuzeon sales in the U.S. and Canada plunged 28 percent to $7.2 million.